Biotech startups in Singapore

Adrian Ang & Rex Tan & Ser Wee **venue:** Singapore (NTU / one-north) **la:** 1.2996 **ln:** 103.7877 **desc:** Founded 2018, an NTU spin-off. AeviceMD is a chest-worn smart wearable stethoscope with an AI platform for continuous remote monitoring of asthma/COPD (wheeze, respiratory rate, heart rate) and early detection of respiratory distress. Raised US$7M Seed Plus led by Coronet Ventures (2024), plus strategic investment from Denka/Pegasus and Elev8.vc (Jan 2025). Named BioSpectrum Asia Startup of the Year 2024. **link:** https://www.aevice.com **vertical:** ["Biotech"] **stage:** Seed Plus -

Founded 2018, an NTU spin-off. AeviceMD is a chest-worn smart wearable stethoscope with an AI platform for continuous remote monitoring of asthma/COPD (wheeze, respiratory rate, heart rate) and early detecti...

(CEO Adam Gridley) **venue:** Singapore + San Francisco Bay Area / San Jose, CA **la:** 1.2988 **ln:** 103.7877 **desc:** "Born in Singapore" ~2017; retains major Singapore operations alongside a US Bay Area team. Develops ultra-sustained, non-opioid post-surgical pain therapies combining validated analgesics with bioresorbable polymers; lead ATX101 targets weeks of relief after knee surgery. Raised US$57.5M Series D + venture debt (June 2025), co-led by Lightstone Ventures and ClavystBio. NOTE: dual SG/US presence — verify primary HQ if strict SG-only. **link:** https://www.allaytx.com **vertical:** ["Biotech"] **stage:** Series D -

Born in Singapore" ~2017; retains major Singapore operations alongside a US Bay Area team. Develops ultra-sustained, non-opioid post-surgical pain therapies combining validated analgesics with bioresorbable ...

(spun from Temasek/A*STAR IP; CEO Suresha Venkataraya) **venue:** Singapore (one-north) + Burbank, CA **la:** 1.2996 **ln:** 103.7877 **desc:** Founded 2007. AWAK PD is a wearable, ultra-portable sorbent-based peritoneal-dialysis system that cuts dialysis-fluid use up to ~90%, enabling on-the-go dialysis for end-stage kidney disease. Raised US$20M+ Series B (2023, co-led Lion X Ventures & Vickers Venture Partners) — one of Singapore's largest medtech rounds — after a US$40M round in 2019; readying US pivotal trial. **link:** https://www.awak.com **vertical:** ["Biotech"] **stage:** Series B -

Founded 2007. AWAK PD is a wearable, ultra-portable sorbent-based peritoneal-dialysis system that cuts dialysis-fluid use up to ~90%, enabling on-the-go dialysis for end-stage kidney disease. Raised US$20M+ ...

Yap Chew Loong & Ng Wan Sing **venue:** Singapore **la:** 1.3048 **ln:** 103.8318 **desc:** Founded 2010, Singapore's first surgical-robotics venture (NUS/clinical roots). iSR'obot Mona Lisa is a robotic MRI/ultrasound-fusion transperineal prostate-biopsy navigation system deployed in hospitals internationally; validated in 2025 single-centre clinical studies (BJU International). **link:** https://biobotsurgical.com **vertical:** ["Biotech"] **stage:** Growth / commercial --- ## Biotech / Therapeutics / Genomics / Diagnostics -

Founded 2010, Singapore's first surgical-robotics venture (NUS/clinical roots). iSR'obot Mona Lisa is a robotic MRI/ultrasound-fusion transperineal prostate-biopsy navigation system deployed in hospitals int...

Piers Ingram (CEO) / launched by Frazier Life Sciences **venue:** US-based (Seattle/Bay Area); IP in-licensed from Singapore's Hummingbird Bioscience **la:** 47.6062 **ln:** -122.3321 **desc:** Launched March 2025 with a US$187M Series A (Frazier Life Sciences, Novo Holdings, Jeito, Omega, ClavystBio, EDBI) — the largest biotech Series A tied to Singapore. Develops multi-payload ADCs (lead HER2 dual-payload) exclusively licensed from Hummingbird Bioscience. INCLUDE only as a Singapore-ecosystem-linked spinout; primary company is US-domiciled, so flag/exclude from strict SG-HQ list. **link:** https://calliotx.com **vertical:** ["Biotech"] **stage:** Series A --- ## Ecosystem context (anchors & health VCs — reference, not company records) - **Biopolis / one-north (JTC):** Singapore's flagship biomedical R&D estate; home to A*STAR institutes (GIS, IMCB, BII, Bioinformatics), NSG BioLabs (35,000 sq ft BSL-2 co-lab space at Biopolis), and many of the biotechs above. - **Anchoring research bodies:** A*STAR, Duke-NUS Medical School, NUS Yong Loo Lin, NTU Lee Kong Chian School of Medicine; co11ab incubator (NTU + A*STAR + National Healthcare Group). - **Health/life-science VCs & builders:** ClavystBio (Temasek + A*STAR venture builder), EDBI, Seeds Capital (Enterprise SG), Sheares Healthcare (Temasek), HealthXCapital, Verge HealthTech Fund, Lightstone Ventures, Vickers Venture Partners, Elev8.vc, Novo Holdings (active regionally).

Launched March 2025 with a US$187M Series A (Frazier Life Sciences, Novo Holdings, Jeito, Omega, ClavystBio, EDBI) — the largest biotech Series A tied to Singapore. Develops multi-payload ADCs (lead HER2 dua...

Jeffrey Lu & Timothy Lu **venue:** Singapore (one-north / Biopolis) + South San Francisco **la:** 1.2996 **ln:** 103.7877 **desc:** Founded 2014/2015. AI- and CRISPR-driven "network biology" drug-discovery platform decoding genetic interactions to develop precision-oncology therapies. Raised ~US$27M Series A extension (Oct 2023; Polaris Partners, 6 Dimensions, Invus, EDBI); ~US$90M+ total. NOTE: co-headquartered/operates in both Singapore and San Francisco — verify primary HQ if strict SG-only. **link:** https://enginebio.com **vertical:** ["Biotech"] **stage:** Series A+ -

Founded 2014/2015. AI- and CRISPR-driven "network biology" drug-discovery platform decoding genetic interactions to develop precision-oncology therapies. Raised ~US$27M Series A extension (Oct 2023; Polaris ...

Piers Ingram & Jerome Boyd-Kirkup **venue:** Singapore (one-north / MedTech Hub) + South San Francisco **la:** 1.2996 **ln:** 103.7877 **desc:** Founded 2015. Uses a rational, systems-biology antibody-discovery platform to build next-gen antibody and ADC therapeutics; lead assets incl. anti-HER3 (HMBD-001) and anti-VISTA (HMBD-002). Raised US$125M Series C led by Novo Holdings (2021); later venture round from Decheng Capital. Spun out ADC platform to Callio Therapeutics (2025). **link:** https://hummingbirdbioscience.com **vertical:** ["Biotech"] **stage:** Series C -

Founded 2015. Uses a rational, systems-biology antibody-discovery platform to build next-gen antibody and ADC therapeutics; lead assets incl. anti-HER3 (HMBD-001) and anti-VISTA (HMBD-002). Raised US$125M Se...

Tan Min-Han **venue:** Singapore (one-north) + Palo Alto, CA **la:** 1.2996 **ln:** 103.7877 **desc:** Founded 2016. Precision-oncology liquid-biopsy company; LiquidHallmark is a blood test profiling 80 genes across 15 cancer types to match patients with targeted therapies. In 2023 became the first Asian-HQ'd company to win US Medicare coverage for its cancer test. Raised US$45M+ across 2022–2023; US$80M+ total; expanding into US and India. **link:** https://www.lucence.com **vertical:** ["Biotech"] **stage:** Series B --- ## Flagged — Singapore-founded but NOT Singapore-HQ (excluded from SG-HQ count) -

Founded 2016. Precision-oncology liquid-biopsy company; LiquidHallmark is a blood test profiling 80 genes across 15 cancer types to match patients with targeted therapies. In 2023 became the first Asian-HQ'd...

Zhou Lihan & Zou Ruiyang & Too Heng-Phon **venue:** Biopolis / JTC MedTech Hub, Singapore (A*STAR/NUS spin-off) **la:** 1.2988 **ln:** 103.7877 **desc:** Founded 2014. microRNA blood-diagnostics company; maker of GASTROClear, the world's first molecular blood test for gastric-cancer screening (~87% early-stage accuracy), and leader of Project CADENCE for multi-cancer early detection. Raised US$77M Series C plus US$40M structured financing (Jan 2025); SE Asia's first biotech to list (HKEX, 2025). ~US$120M+ raised. **link:** https://mirxes.com **vertical:** ["Biotech"] **stage:** Series C / IPO (HKEX 2025) -

Founded 2014. microRNA blood-diagnostics company; maker of GASTROClear, the world's first molecular blood test for gastric-cancer screening (~87% early-stage accuracy), and leader of Project CADENCE for mult...

Astrid Irwanto & Levana Sani & Jianjun Liu & Alexander Lezhava **venue:** Singapore (Biopolis, A*STAR GIS spin-off) **la:** 1.2988 **ln:** 103.7877 **desc:** Founded 2016, an A*STAR Genome Institute of Singapore spin-off. End-to-end pharmacogenomics and genetic-screening company delivering population-relevant tests (e.g. nationwide drug-reaction screening for leprosy patients in Indonesia). Raised ~US$12.6M Series A (2022; East Ventures, Intudo, Vulcan); ~US$13.6M total. **link:** https://nalagenetics.com **vertical:** ["Biotech"] **stage:** Series A -

Founded 2016, an A*STAR Genome Institute of Singapore spin-off. End-to-end pharmacogenomics and genetic-screening company delivering population-relevant tests (e.g. nationwide drug-reaction screening for lep...

Lynne Lim & Gan Chee Wee **venue:** Singapore (central) **la:** 1.3048 **ln:** 103.8318 **desc:** Founded 2021. CLiKX is the world's first handheld robotic ear-tube surgical applicator for otitis media with effusion ("glue ear"), aiming to make grommet insertion a fast in-clinic procedure. Raised ~US$7.5M; won MedTech Innovator APAC Grand Prize 2022. Founder Dr Lynne Lim is a 2024 Cartier Women's Initiative fellow. **link:** https://www.nousq.com **vertical:** ["Biotech"] **stage:** Early / Series A -

Founded 2021. CLiKX is the world's first handheld robotic ear-tube surgical applicator for otitis media with effusion ("glue ear"), aiming to make grommet insertion a fast in-clinic procedure. Raised ~US$7.5...

Yann Chong Tan **venue:** Singapore (Biopolis, A*STAR spin-off) **la:** 1.2988 **ln:** 103.7877 **desc:** Founded 2021, an A*STAR spin-off. Gene-therapy company built on its PrOSIA mechanobiology platform to treat genetic cardiomyopathies; lead candidate NVC-001 targets LMNA-related dilated cardiomyopathy heading to Phase 1/2. Closed US$45M Series B (May 2025) co-led by Kurma Partners and Angelini Ventures (incl. EDBI, ClavystBio, Boehringer Ingelheim Venture Fund). **link:** https://www.nuevocor.com **vertical:** ["Biotech"] **stage:** Series B -

Founded 2021, an A*STAR spin-off. Gene-therapy company built on its PrOSIA mechanobiology platform to treat genetic cardiomyopathies; lead candidate NVC-001 targets LMNA-related dilated cardiomyopathy headin...